On 23 April 2021, the grand opening of a full-cycle production line for the drug Ixazomib (Ninlar®) of the Takeda Pharmaceutical Company took place in Yaroslav.
Takeda is an associate member of the RSPP, and one of the first foreign pharmaceutical corporations to build their own production facility in Russia in Yaroslavl Oblast.
Total investment in construction and localisation for the period from 2010 to 2018 amounted to around EUR 100 million. The plant is capable of producing 90 million ampoules and over 3 billion tablets per year, which fully meets demand in Russia for these drugs, and also opens up export opportunities.
Ixazomib (Ninlar®), a drug developed to treat multiple myeloma, is now ready for production at the plant. This will give Russian patients access to innovative therapies, and improve the quality of their lives and life expectancy.
President of the RSPP, A. N. Shokhin, sent a message of greetings to staff of the Takeda Company.